/DERM

DERM Stock - Journey Medical Corporation

Q: What is the analyst price target for DERM?

Analyst price target information is not currently available for DERM.

Q: What is DERM's market cap?

Market capitalization information is not currently available for DERM.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$8.00+3.36%

+$0.26 (+3.36%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+46.9%upside

Target: $11.75

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for DERM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.82

52W High$9.40

52W Low$3.54

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$56.13M	$79.18M	$73.67M	$63.13M	$44.53M
Gross Profit	$35.26M	$52.52M	$42.89M	$31.05M	$29.94M
Gross Margin	62.8%	66.3%	58.2%	49.2%	67.2%
Operating Income	$-13,677,000	$-2,073,000	$-27,517,000	$-34,881,000	$7.85M
Net Income	$-14,672,000	$-3,853,000	$-29,628,000	$-43,994,000	$5.28M
Net Margin	-26.1%	-4.9%	-40.2%	-69.7%	11.9%
EPS	$-0.72	$-0.21	$-1.69	$-2.54	$0.32

Company Overview

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Visit Website

Earnings History & Surprises

DERM

Beat Rate

29%

Last 17 quarters

Avg Surprise

-11.4%

EPS vs Estimate

Beats / Misses

5/12

Last 12 quarters

Latest EPS

$-0.09

Q4 2025

EPS Surprise History

Q1 24

-50.0%

$-0.12vs$-0.08

Q2 24

-103.8%

$-0.53vs$-0.26

Q3 24

-13.3%

$-0.17vs$-0.15

Q4 24

+29.4%

$-0.12vs$-0.17

Q1 25

+136.4%

$0.08vs$-0.22

Q2 25

+25.0%

$-0.18vs$-0.24

Q3 25

-128.6%

$-0.16vs$-0.07

Q4 25

-12.5%

$-0.09vs$-0.08

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 25, 2026	$-0.06	—	—	—
Q1 2026	Mar 19, 2026	—	—	—	—
Q4 2025	Nov 12, 2025	$-0.08	$-0.09	-12.5%	✗ MISS
Q3 2025	Aug 12, 2025	$-0.07	$-0.16	-128.6%	✗ MISS
Q2 2025	May 14, 2025	$-0.24	$-0.18	+25.0%	✓ BEAT
Q1 2025	Mar 26, 2025	$-0.22	$0.08	+136.4%	✓ BEAT
Q4 2024	Nov 12, 2024	$-0.17	$-0.12	+29.4%	✓ BEAT
Q3 2024	Aug 12, 2024	$-0.15	$-0.17	-13.3%	✗ MISS
Q2 2024	May 13, 2024	$-0.26	$-0.53	-103.8%	✗ MISS
Q1 2024	Mar 21, 2024	$-0.08	$-0.12	-50.0%	✗ MISS
Q4 2023	Nov 7, 2023	$-0.15	$0.80	+633.3%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.34	$-0.46	-35.3%	✗ MISS
Q2 2023	May 22, 2023	$-0.44	$-0.57	-29.5%	✗ MISS
Q1 2023	Mar 29, 2023	$-0.37	$-0.60	-62.2%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.34	$-0.57	-67.6%	✗ MISS
Q3 2022	Aug 9, 2022	$-0.25	$-0.43	-72.0%	✗ MISS
Q2 2022	May 10, 2022	$-0.18	$-0.08	+55.6%	✓ BEAT
Q1 2022	Mar 23, 2022	$-0.29	$-1.64	-465.5%	✗ MISS
Q4 2021	Dec 10, 2021	$-0.87	$-1.16	-33.6%	✗ MISS
Q4 2021	Nov 12, 2021	—	$-1.30	—	—

Frequently Asked Questions about DERM

What is DERM's current stock price?

Journey Medical Corporation (DERM) is currently trading at $8.00 per share. The stock has moved +3.36% today.

What is the analyst price target for DERM?

The average analyst price target for DERM is $11.75, based on 1 analyst.

What sector is Journey Medical Corporation in?

Journey Medical Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is DERM's market cap?

Journey Medical Corporation has a market capitalization of $0.18 billion, making it a small-cap company.

Does DERM pay dividends?

No, Journey Medical Corporation does not currently pay a dividend to shareholders.